skip navigation


Register for Latest Research

Stay Informed
Register with NCJRS to receive NCJRS's biweekly e-newsletter JUSTINFO and additional periodic emails from NCJRS and the NCJRS federal sponsors that highlight the latest research published or sponsored by the Office of Justice Programs.

NCJRS Abstract

The document referenced below is part of the NCJRS Virtual Library collection. To conduct further searches of the collection, visit the Virtual Library. See the Obtain Documents page for direction on how to access resources online, via mail, through interlibrary loans, or in a local library.


NCJ Number: 161633 Find in a Library
Title: LAAM (Levo Alpha AcetylMethadol Hydrochloride): Another Treatment for Opiate Addiction
Corporate Author: National Institute on Drug Abuse
United States of America
Project Director: A Forman
Date Published: 1995
Page Count: 0
Sponsoring Agency: National Institute on Drug Abuse
Bethesda, MD 20892-9561
Sale Source: National Institute on Drug Abuse
National Institutes of Health
6001 Executive Boulevard, Room 5213
Bethesda, MD 20892-9561
United States of America
Type: Citizen Involvement Material
Language: English
Country: United States of America
Annotation: This video describes drug treatment for opiate addiction through the use of the substitute drug LAAM (Levo Alpha AcetylMethadol Hydrochloride) and compares such treatment with Methadone maintenance treatment.
Abstract: Patients, ex-patients, and treatment staff describe the characteristics and impact of LAAM treatment, noting where it differs from methadone treatment. LAAM suppresses withdrawal symptoms for persons who have stopped using opiates, so that they are able to function normally and without the pain and craving associated with withdrawal from opiate addiction. The distinctive characteristics of LAAM are its lack of a sedative effect, in contrast to methadone, and its longer duration of impact (48 to 72 hours) compared to methadone (24 hours). Patients who have been on both methadone and LAAM describe their preference for LAAM. Using visual animation, the video explains how LAAM works in the body to achieve its effects. Also discussed are the history of LAAM's development and testing that led to FDA approval for its use in drug treatment in 1993, how to introduce patients to LAAM treatment, and the characteristics of those who are good candidates for LAAM treatment.
Main Term(s): Drug treatment programs
Index Term(s): Methadone maintenance; Opioids
Note: Color VHS video, 15:19 minutes.
To cite this abstract, use the following link:

*A link to the full-text document is provided whenever possible. For documents not available online, a link to the publisher's website is provided. Tell us how you use the NCJRS Library and Abstracts Database - send us your feedback.